NEXEL
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
21 Wangsan-ro Dongdaemun-gu, Seoul, Seou...Phone Number
+82 220888884Website
www.nexel.co.krRevenue
<$5 MillionIndustry
About NEXEL
NEXEL Org Chart
Is NEXEL your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on NEXEL recently announced quarterly report
Check out if NEXEL is spiking on competitors!
Funding: Get notified immidiatlly once NEXEL has new funding data
NEXEL, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at NEXEL
Click to see if NEXEL had a recent Job posting/layoffs
Product Launch: Get notified when NEXEL launches new products
Check if NEXEL has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined NEXEL as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
NEXEL is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NEXEL is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NEXEL.
NEXEL Tech Stack
A closer look at the technologies used by NEXEL
NEXEL News & Media
Celogics License in NEXEL's Cardiosight-S for Global Distribution
SEATTLE--(BUSINESS WIRE)--Celogics, a U.S.-based manufacturer of human iPSC-derived cell products for therapeutics development and life sciences research, today announced the exclusive licensing of NEXEL’s Cardiosight-S, a leading iPSC-derived cardiomyocyte product line. At the same time, Celogics announced the planned construction of a 20,000 ft2 biomanufacturing facility nearby Seattle, Washington. This facility will be used to manufacture high-quality iPSC-derived cell products utilizing theCuri Bio and NEXEL Announce Celogics, Joint Venture to Develop Leading iPSC-derived Cell Products
SEATTLE & SEOUL, South Korea--(BUSINESS WIRE)-- #biotech--Curi Bio and NEXEL Announce Celogics, Joint Venture Based in Seattle to Develop Leading iPSC-derived Cell Products for Drug Discovery & Safety Testing
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NEXEL
NEXEL is a biotechnology company commercializing "Korea's first" induced pluripotent stem cell (iPSC)-derived cell products. NEXEL partners with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the most accurate product quality data for cardiac safety. NEXEL expertise in iPSC-derived card... Read More